Literature DB >> 27995272

[Mastocytosis : Clinical aspects, diagnostics, therapy].

U Lippert1.   

Abstract

Mastocytosis is a rare, almost exclusively sporadically occurring disease involving an increase in clonal tissue mast cells. The disease spectrum is heterogenous, ranging from isolated skin lesions with a normal life expectancy to rare, aggressive forms with very poor prognosis. Children are often affected. But whereas these almost invariantly display solely a cutaneous mastocytosis with polymorphous skin lesions, in adults the lesions are small and maculopapular and in over 80% of cases accompanied by involvement of bone marrow and the D816V activating mutation of the gene for the c‑Kit receptor. There are many symptoms for the disease. Patients suffer frequently from pruritus, diarrhea, abdominal cramp, palpitations and flush. Osteoporosis is often present, with osteolysis with pathological fractures frequently involved in more aggressive forms. Patients are especially at risk to severe anaphylaxis caused by hymenoptera stings. Therapy is symptomatic, with cytoreductive therapy reserved for resistant and aggressive forms.

Entities:  

Keywords:  Anaphylaxis; Mast cell activation syndrome; Osteoporosis; Tryptase; WHO classification

Mesh:

Year:  2017        PMID: 27995272     DOI: 10.1007/s00105-016-3911-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  17 in total

1.  Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis.

Authors:  Tim Wiechers; Anja Rabenhorst; Tina Schick; Liane M Preussner; Anja Förster; Peter Valent; Hans-Peter Horny; Karl Sotlar; Karin Hartmann
Journal:  J Allergy Clin Immunol       Date:  2015-07-04       Impact factor: 10.793

2.  Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.

Authors:  Anja Gunda Jung; Hans-Peter Horny; Karl Sotlar; Tobias Overbeck; Michael Peter Schön; Undine Lippert
Journal:  J Am Acad Dermatol       Date:  2011-07       Impact factor: 11.527

Review 3.  Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI position paper.

Authors:  P Bonadonna; M Pagani; W Aberer; M B Bilò; K Brockow; H Oude Elberink; L Garvey; H Mosbech; A Romano; R Zanotti; M J Torres
Journal:  Allergy       Date:  2015-04-24       Impact factor: 13.146

Review 4.  Hymenoptera Allergy and Mast Cell Activation Syndromes.

Authors:  Patrizia Bonadonna; Massimiliano Bonifacio; Carla Lombardo; Roberta Zanotti
Journal:  Curr Allergy Asthma Rep       Date:  2016-01       Impact factor: 4.806

Review 5.  [Childhood-onset mastocytosis].

Authors:  F Siebenhaar; K Weller; U Blume-Peytavi; M Maurer
Journal:  Hautarzt       Date:  2012-02       Impact factor: 0.751

Review 6.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

7.  Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.

Authors:  Animesh Pardanani
Journal:  Am J Hematol       Date:  2016-11       Impact factor: 10.047

Review 8.  Gastrointestinal involvement and manifestations in systemic mastocytosis.

Authors:  Harry Sokol; Sophie Georgin-Lavialle; Catherine Grandpeix-Guyodo; Danielle Canioni; Stéphane Barete; Patrice Dubreuil; Olivier Lortholary; Laurent Beaugerie; Olivier Hermine
Journal:  Inflamm Bowel Dis       Date:  2010-07       Impact factor: 5.325

Review 9.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

10.  Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis.

Authors:  P Valent; L Escribano; S Broesby-Olsen; K Hartmann; C Grattan; K Brockow; M Niedoszytko; B Nedoszytko; J N G Oude Elberink; T Kristensen; J H Butterfield; M Triggiani; I Alvarez-Twose; A Reiter; W R Sperr; K Sotlar; S Yavuz; H C Kluin-Nelemans; O Hermine; D Radia; J J van Doormaal; J Gotlib; A Orfao; F Siebenhaar; L B Schwartz; M Castells; M Maurer; H-P Horny; C Akin; D D Metcalfe; M Arock
Journal:  Allergy       Date:  2014-05-19       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.